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Abstract: Various interesting heterocycle skeletons were synthesized via Michael type addition reaction with 1,2; 1,3-bidentate nitrogen 
and carbon nucleophiles. Cycloaddition of different α,β–unsaturated systems afforded bromopyrimidinone 3/5, bromothiazine 4 and 
bromopyrazole 6a/6b pyrazole-1-carboxylate 8, pyridinylmethanone 9, nicotinonitrile 10, pyrazolopyridine 11a/11b, pyran-3-carbonitrile 
12/13, chromenopyridine 14 and N-butyrylpyrazolyl-1-butanone 15 derivatives. The structures of the synthesized compounds were 
elucidated based on IR, NMR and mass spectral analyses. Group of the newly synthesized compounds were screened for their anti-diabetic 
activities, whereas compounds 8 and 11b exhibited promising anti-diabetic activities at micro molar concentration against α-glucosidase 
inhibitor with IC50 values ranging between 13.80-500 μM. On the other hand compound 10 showed a week effect as compared to the 
standard anti-diabetic agent. 
 





ITROGEN-containing heterocyclic molecules consti-
tute the largest portion of chemical entities, which 
are part of many natural products, fine chemicals, and 
biologically active pharmaceuticals, which are vital for 
enhancing quality of life.[1–11] In this respect and various 
approaches for the preparation of these privileged 
structures with drug-like properties have been developed 
on various synthetic strategies. Pyrimidines, as the most 
important nitrogen-containing heterocyclic compounds, 
are of chemical and pharmacological interest. Many 
studies have been shown that compounds containing the 
pyrimidine ring possess antidiabetic, antibacterial, anti-
fungal, antimalarial, and anticonvulsant activities,[12–16] 
and anticancer activities,[17,18] and many of pyrimidine 
compounds were reported to act as calcium channel 
blockers,[19] and as potential central nervous system (CNS) 
depressants.[20,21] Also, Pyrazoline derivatives widely occur 
in the environment, in the form of alkaloids, vitamins and  
 
pigments as constituents of plant and animal cell. 
Considerable attention has been carried out on the 
pyrazolines and substituted pyrazolines due to their 
inspiring biological activities such as antibacterial, 
antifungal,[22–24] antidepressant,[25–28] anticonvulsant,[29] 
and antitumor,[30] properties. The pyrazoline, a versatile 
moiety is present as the core constituent in a variety of 
leading drugs such as Sildenafil, Celebrex, and Rimonabant 
etc. The fact that α,β-unsaturated carbonyl compounds are 
push-pull olefins, and Michael acceptors permits them as 
adaptable intermediates in the synthesis of many azole and 
azine molecules.[31] Changes in their structure have offered 
a high degree of diversity that has proven useful for the 
development of new therapeutic agents having improved 
potency and lowered toxicity. Based on the above 
considerations and in continuation of our research on 
biologically potent heterocyclic derivatives,[32–38] herein, 
we report the synthesis, structural elucidation and anti-
diabetic activity of some new azoles and azines prepared 
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All melting points were determined using a Stuart melting 
point apparatus by the open capillary tube method and 
are uncorrected. IR spectra were recorded on a FT-IR 
JASCO 6100 instrument in KBr phase. 1H NMR and 13C 
NMR spectra were recorded on a Varian spectrometer 
(300 MHz) in DMSO-d6 as solvent, using TMS as internal 
standard and chemical shifts are expressed as δ ppm. The 
mass spectra were recorded by ISQ LT single quadrupole 
mass spectrometer. In vitro antimicrobial activities were 
carried out at the Regional Center for Mycology and 
Biotechnology, Al-Azhar University, Egypt. Elemental 
analyses were performed by the Micro Analytical Center, 
Cairo University, Egypt and are within 0.4 % of the 





en-1-one (7b) was prepared as described in the 
literature.[31] The progress of the reaction and the purity 
of the compounds were routinely monitored on TLC by 
pre-coated aluminum silica gel 60F254 thin layer plates 
obtained from Merck (Germany) eluting with petroleum 
ether/ethyl acetate. The yields of all products were not 
optimized. All reagents used were obtained from 
commercial sources. All solvents were of analytical grade 
and used without further purification. 
Synthesis of Phenyl(2-phenyl-3,4-dihydro-
2H-1,4-benzothiazin-3-yl)methanone (2) 
A mixture of 2,3-dibromo-1,3-diphenylpropan-1-one (1a) 
(3.68 g, 10 mmol) and 2-aminobenzenethiol (1.25 g,  
10 mmol) in methanol (30 mL) was stirred at r.t. for 30 min, 
then refluxed for 1 h. After removal of the solvent under 
vacuum, water was added. The precipitated solid was 
filtered off, washed with water, dried and recrystallized 
from methanol to give 2. Yield 80 % (2.65 g); green crystals; 
m.p. 160–162 °C; IR (KBr) ṽ / cm–1: 3347 (NH), 3059, 3025 
(CH aromatic), 2922, 2875 (CH aliphatic), 1677 (C=O), 1589 
(C=C); 1H NMR (400 MHz, DMSO-d6) δ / ppm: 8.31–7.37 (m, 
14H, Ar-H), 6.69 (d, 1H, J = 11.32 Hz, SCH), 5.78 (d, 1H, J 
= 11.32 Hz, CH-Ar), 3.61 (s, 1H, NH); 13C NMR spectrum 
(75 MHz, DMSO-d6) δ / ppm: 192.03, 144.60, 138.84, 
137.92, 135.13, 134.07, 133.68, 131.18, 129.59, 129.64, 
129.44, 129.31, 129.24, 128.96, 128.46, 128.35, 127.83, 
122.46, 51.26, 46.77; MS m / z: 333 (M+ + 2), 332 (M+ + 
1), 331 (M+), 330 (M+ – 1), 229 (M+ – 2), 69(100); Anal. 
Calcd mass fractions of elements, w / %, for C21H17NOS 
(Mr = 331.43) are: C, 76.10; H, 5.17; N, 4.23. Found: C, 
76.32; H, 5.34; N, 4.72. 
 
General Procedure for Synthesis of 
Pyrimidin-2(1H)-one 3, Thiazine 4, 
Dihydropyrimidin-2(1H)-one 5, Pyrazole 
6a and 6b Derivatives 
A mixture of 2,3-dibromo ketone derivative 1a/1b  
(10 mmol), urea, thiourea, semicarbazide (0.75 g, 10 mmol) 
or hydrazine hydrate 99 % (15 mmol) in presence of AcONa 
(10 g) in AcOH (30 mL) was refluxed for 5–7 hours. Water 
was added after removal of the solvent under vacuum. The 
solid precipitated was filtered off, washed with water, dried 
and recrystallized from the proper solvent to give 3, 4, 5, 6a 




Yield 57 % (2.23 g); green crystals; recrystallized from 
benzene; m.p. 146–148 °C; IR (KBr) ṽ / cm–1: 3430 (NH), 
3113, 3063 (CH aromatic), 2925, 2852 (CH aliphatic), 1653 
(C=O), 1586 (C=N); 1H NMR (300 MHz, DMSO-d6) δ / ppm: 
8.07 (s, 1H, NH), 8.06–7.06 (m, 8H, Ar–H), 3.79 (s, 3H, 
OCH3); 13C NMR (75 MHz, DMSO-d6) δ / ppm: 189.33 (C=O), 
156.41 (C=N), 138.01, 137.15, 134.37, 134.03, 131.44, 
131.26, 128.80, 124.28, 123.48, 113.65, 111.29 (aromatic 
carbons), 56.17 (OCH3); MS m / z: 394 (1.53) (M+ + 2), 392 
(2.00) (M+), 161(100); Anal. Calcd mass fractions of 
elements, w / %, for C17H12BrClN2O2 (Mr = 391.64) are: C, 




Yield 67 % (2.74 g); yellow crystals; recrystallized from 
petroleum ether 60 / 80; m.p. 124–126 °C; IR (KBr) ṽ / cm–1: 
3417 (NH), 2923, 2852 (CH aliphatic), 1658 (C=N), 1591 
(C=C); 1H NMR (300 MHz, DMSO-d6) δ / ppm: 8.21-7.04 (m, 
10H, Ar-H + D2O exchangeable NH), 3.88 (s, 3H, OCH3), 3.78 
(s, 1H, Ar-CH); 13C NMR (75 MHz, DMSO-d6) δ / ppm: 
187.84, 157.34, 138.14, 136.94, 136.07, 134.41, 131.44, 
130.42, 130.24, 128.77, 125.06, 122.58, 114.03, 113.62, 
112.51, 56.17 (OCH3), 56.07 (ArCH); MS m / z: 411(2.61) (M+ 
+ 2), 409 (5.64) (M+), 69 (100); Anal. Calcd mass fractions of 
elements, w / %, for C17H14BrClN2OS (Mr = 409.72) are: C, 




Yield 75 % (3.06 g); colorless crystals; recrystallized from 
petroleum ether 60 / 80; m.p. 162–164 °C; IR (KBr) ṽ / cm–1: 
3450 (NH), 3287, 3221 (NH2), 2962, 2928, 2846 (CH 
aliphatic), 1677 (C=O), 1590 (C=C); 1H NMR (300 MHz, 
DMSO-d6) δ / ppm: 8.23–7.03 (m, 8H, Ar-H), 6.60 (s, 3H, D2O 
exchangeable, NH + NH2),  3.76 (s, 3H, OCH3), 3.53 (s, 1H, 
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145.95, 143.95, 133.19, 131.42, 130.38, 128.25, 127.66, 
126.78, 122.41, 114.63, 112.34, 91.68, 55.94 (ArCH), 54.90 
(OCH3); MS (m / z, %): 329, 328 (M+ – Br), 102 (100); Anal. 
Calcd mass fractions of elements, w / %, for C17H15BrClN3O2 
(Mr = 408.67) are: C, 49.96; H, 3.70; N, 10.28. Found: C, 
49.79; H, 3.81; N, 10.61. 
 
4-BROMO-3,5-DIPHENYL-1H-PYRAZOLE (6a) 
Yield 83 % (2.48 g); colorless crystals; recrystallized from 
petroleum ether 60 / 80; m.p. 202–204 °C; IR (KBr) ṽ / cm–1: 
3445 (NH), 3095, 3063, 3003 (CH aromatic), 1608 (C=N), 
1578 (C=C); 1H NMR (300 MHz, DMSO-d6) δ / ppm: 13.35 
(1H, s, D2O exchangeable, NH), 7.89–7.17 (10H, m, Ar–H); 
13C NMR spectrum (75 MHz, DMSO-d6) δ / ppm: 151.34, 
143.37 (pyrazole carbons), 133.67, 129.33, 128.93, 128.57, 
128.05, 127.39, 125.10, 124.68 (aromatic carbons), 99.54 
(C–Br); MS m / z: 301 (M+ + 2), 299 (M+), 223, 222 (M+ – 
C6H5), 221, 220 (100), 219 (M+ – Br); Anal. Calcd mass 
fractions of elements, w / %, for C15H11BrN2 (Mr = 299.16) 





Yield 80 % (2.91 g); colorless crystals; recrystallized from 
benzene; m.p. 190–192 °C; IR (KBr) ṽ / cm–1: 3280 (NH), 
3140 (CH aromatic), 2980, 2922, 2838 (CH aliphatic), 1580 
(C=N); 1H NMR (300 MHz, DMSO-d6) δ / ppm: 7.98–7.10 (m, 
9H, Ar–H + D2O exchangeable NH), 3.92 (s, 3H, OCH3); 13C 
NMR (75 MHz, DMSO-d6) δ / ppm: 155.02, 131.95, 131.38, 
129.53, 128.69, 126.71, 114.21, 112.14, 102.84 (aromatic 
carbons), 55.84 (OCH3); MS m / z: 365 (M+ + 2), 364 (M+ + 
1), 363 (M+), 362 (M+ – 1), 361 (M+ – 2), 174(100); Anal. 
Calcd mass fractions of elements, w / %, for C16H12BrClN2O 
(Mr = 363.63) are: C, 52.85; H, 3.33; N, 7.70. Found: C, 
52.52; H, 3.26; N, 7.97. 
Synthesis of Tert-butyl 5-(4-
chlorophenyl)-3-(2-methoxyphenyl)-2,3-
dihydro-1H-pyrazole-1-carboxylate (8) 
A mixture of 7a (2.72 g, 10 mmol), tert-carbazate (10 mmol) 
in ethanol (30 mL) was heated under reflux for 5 h. The 
reaction mixture was concentrated under reduced 
pressure, cooled and ice cold water was added. The 
product formed was filtered off, washed with water, dried 
and recrystallized from petroleum ether 60 / 80 to give 8. 
Yield 60 % (2.32 g); yellow crystals; m.p. 136–138 °C; IR 
(KBr) ṽ / cm–1: 3426 (NH), 3257, 3045 (CH aromatic), 2975, 
2928 (CH aliphatic), 1707(C=O), 1604 (C=C); 1H NMR (300 
MHz, DMSO-d6) δ / ppm: 10.81 (s, 1H, D2O exchangable, 
NH), 8.36–6.93 (m, 9H, Ar-H and ethenylic CH), 3.80 (s, 3H, 
OCH3), 2.18 (s, 1H, methinyl CH), 1.46 (s, 9H, tert-butyl); 13C 
NMR (75 MHz, DMSO-d6) δ/ppm: 157.20 (C=O), 152.43, 
138.58, 130.63, 128.14, 127.55, 125.14, 122.71, 120.52, 
111.57, 79.20, 55.50 (s, 3H, OCH3), 28.03 (s, 9H, CH3); MS  
m / z: 389 (M+ + 2), 387 (M+),  54(100); Anal. Calcd mass 
fractions of elements, w / %, for C21H23ClN2O3 (Mr = 386.87) 





A mixture of 7a (2.72 g, 10 mmol) and ammonium acetate 
(10 g) in acetic acid (30 mL) was refluxed for 1 h. After 
removal of the solvent under vacuum, ice cold water was 
added and the resultant solution was neutralized with 
diluted HCl. The solid formed was filtered off, washed with 
water, dried and recrystallized from methanol to give 9. Yield 
50 % (2.70 g); colorless crystals; m.p. 170–172 °C; IR (KBr) ṽ / 
cm–1: 3065 (CH aromatic), 2923, 2830 (CH aliphatic), 1658 
(C=O), 1601 (C=N); 1H NMR (300 MHz, DMSO-d6) δ / ppm: 
8.27–7.09 (m, 17H, Ar-H and CH pyridine), 3.83 (s, 6H, 
2OCH3); 13C NMR (75 MHz, DMSO-d6) δ / ppm: 154.48 (C=O), 
148.30 (C=N), 137.51, 134.01, 130.50, 128.75, 128.55, 
120.90, 119.64, 111.95 (aromatic carbons), 55.72 (OCH3); MS 
m / z: 541 (M+), 115 (100); Anal. Calcd mass fractions of 
elements, w / %, for C32H23Cl2NO3 (Mr = 540.43) are: C, 71.12; 
H, 4.29; N, 2.59. Found: C, 70.82; H, 4.09; N, 2.26. 
General Procedure for Synthesis of 
Nicotinonitrile 10,Pyrazolopyridine 11a 
and 11b Derivatives 
A mixture of 7a/7b (10 mmol) with malononitrile and/or  
N-phenyl pyrazolone derivative (10 mmol) in acetic acid  
(30 mL) in presence of ammonium acetate (10 g) was 
refluxed for 10 h. After removal of the solvent under 
vacuum, water was added and the resultant solution was 
neutralized with diluted HCl. The precipitated solid was 
filtered off, washed with water, dried and recrystallized 




Yield 65 % (2.18 g); recrystallized from acetic acid; orange 
crystals; m.p. 218–220 °C; IR (KBr) ṽ / cm–1: 3449, 3348, 
3226 (NH…NH2), 3073, 3026 (CH aromatic), 2970, 2937 (CH 
aliphatic), 2217 (CN), 1632 (C=N), 1599 (C=C); 1H NMR (300 
MHz, DMSO-d6) δ / ppm: 8.12–6.93 (m, 9H, Ar–H and CH 
pyridine), 3.80 (s, 3H, OCH3), 3.36 (s, 2H, D2O exchangable, 
NH2); 13C NMR (75 MHz, DMSO-d6) δ / ppm: 155.61, 154.71, 
149.98, 134.02, 130.55, 130.51, 128.53, 128.12, 127.99, 
125.16, 120.13, 111.13, 55.42, 55.35, 41.06; MS m / z: 338 (M+ 
+ 2), 337 (M+ + 1), 336 (M+), 40 (100); Anal. Calcd mass fractions 
of elements, w / %, for C19H14ClN3O (Mr = 335.78) are: C, 67.96; 
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Yield 75 % (3.19 g); recrystallized from methanol; yellow 
crystals; m.p. 178–180 °C; IR (KBr) ṽ / cm–1: 3073, 3001 (CH 
aromatic), 2954, 2926, 2828 (CH aliphatic), 1600 (C=N); 1H 
NMR (300 MHz, DMSO-d6) δ / ppm: 8.27-7.09 (m, 14H, Ar–
H and CH pyridine), 3.84 (s, 6H, 2CH3); 13C NMR (75 MHz, 
DMSO-d6) δ / ppm: 176.57, 156.33, 154.45, 148.26, 137.48, 
133.98, 130.46, 128.71, 128.51, 127.08, 120.87, 120.45, 
119.61, 111.91 (aromatic carbon), 55.69 (OCH3), 40.33 
(CH3); MS m / z: 428 (M+ + 2), 427 (M+ + 1), 426 (M+), 131 
(100); Anal. Calcd mass fractions of elements, w / %, for 
C26H20ClN3O (Mr = 425.90) are: C, 73.32; H, 4.73; N, 9.87. 




Yield 61 % (2.51 g); recrystallized from methanol / water; 
brown crystals; m.p. 312–314 °C; IR (KBr) ṽ / cm–1: 3428 
(OH), 3065 (CH aromatic), 2859 (CH aliphatic), 1601 (C=N); 
1H NMR (300 MHz, DMSO-d6) δ / ppm: 11.58 (s, 1H, D2O 
exchangable, OH), 8.15–7.20 (m, 14H, Ar-H and CH 
pyridine), 2.16 (s, 3H, CH3); MS m / z: 413 (M+ + 2), 411 (M+), 
83 (100); Anal. Calcd mass fractions of elements, w / %, for 
C25H18ClN3O (Mr = 411.88) are: C, 72.90; H, 4.40; N, 10.20. 




A mixture of 7b (2.58 g, 10 mmol), malononitrile (0.66 g,  
10 mmol) and ten drops of TEA in DMF (30 mL) was heated 
under reflux for 9 h, and then cooled, poured into ice-cold 
water and acidified with acetic acid. The precipitated solid 
was filtered off, dried and recrystallized from methanol to 
give 12. 
 Yield 48 % (1.56 g); brown crystals; m.p. 268–270 °C; 
IR (KBr) ṽ / cm–1: 3429 (OH), 3235 (NH), 3074 (CH aromatic), 
2202 (CN), 1601 (C=N); 1H NMR (300 MHz, DMSO-d6)  
δ / ppm: 8.98 (s, 1H, OH), 8.86 (s, 1H, NH), 8.02–7.06 (m, 
9H, Ar-–H and CH pyran), 3.45 (d, 1H, J = 6.9 Hz, CH), 3.40 
(d, 1H, J = 7.2 Hz, CH); MS m / z: 326 (M+ + 2), 324 (M+), 323 
(M+ – 1), 43(100); Anal. Calcd mass fractions of elements,  
w / %, for C18H13ClN2O2 (Mr = 324.76) are: C, 66.57; H, 4.03; 
N, 8.63. Found: C, 66.58; H, 3.96; N, 8.37. 
General Procedure for Synthesis of 
Pyran-3-carbonitrile 13 and 
Chromenopyridine 14 
A mixture of 7b (2.58 g, 10 mmol) and/or cyanoacetamide, 
malonamide (10 mmol) in 50 mL ethoxide solution 
[prepared by dissolving (0.46 g, 20 mmol) of Na in 50 mL 
abs. ethanol] was heated under reflux for 7 h. After removal 
of the solvent under vacuum, water was added and the 
alkaline solution was neutralized with diluted HCl. The 
product formed was filtered off, washed with cold water, 
dried and recrystallized from the proper solvent to give 13 




Yield 55 % (1.78 g); green crystals; recrystallized from 
methanol; m.p. 320–322 °C; IR (KBr) ṽ / cm–1: 3409 (OH), 
3038 (CH aromatic), 2226 (CN), 1771 (C=O), 1614 (C=C); 1H 
NMR (300 MHz, DMSO-d6) δ / ppm: 10.10 (s, 1H, OH), 8.50–
6.79 (m, 8H, Ar-H); MS m / z: 326 (M+ + 2), 325 (M+ + 1), 324 
(M+), 323(100) (M+ – 1); Anal. Calcd mass fractions of 
elements, w / %, for C18H10ClNO3 (Mr = 323.72) are: C, 




Yield 60 % (1.94 g); colorless crystals; recrystallized from 
acetic acid; m.p. 350–352 °C; IR (KBr) ṽ / cm–1: 3433 (NH), 
3068, 3035 (CH aromatic), 1777, 1638 (C=O), 1616 (C=C); 1H 
NMR (300 MHz, DMSO-d6) δ / ppm: 12.42 (s, 1H, D2O 
exchangable, NH), 8.50-7.36 (m, 9H, Ar-H and 1H, pyridone-
H1); MS m / z: 326 (M+ + 2), 325 (M+ + 1), 324 (M+), 323 (100) 
(M+ – 1); Anal. Calcd mass fractions of elements, w / %, for 
C18H10ClNO3 (Mr = 323.73) are: C, 66.78; H, 3.11; N, 4.33. 




A mixture of 7b (2.72 g, 10 mmol) and hydrazine hydrate 99 
% (15 mmol) in butyric acid (20 mL) was refluxed for 10 h. 
The reaction mixture was concentrated under reduced 
pressure, cooled and neutralized with 5 % sodium 
carbonate solution. The separated solid was filtered off, 
washed with water, dried and recrystallized from methanol 
to give 15. Yield 72 % (2.97 g); yellowish crystals; m.p. 178–
180 °C; IR (KBr) ṽ / cm–1: 3226 (OH), 3190 (CH aromatic), 
2962, 2877 (CH aliphatic), 1638 (C=O), 1594 (C=C); 1H NMR 
(300 MHz, DMSO-d6) δ / ppm: 9.62 (s, 1H, OH), 7.79–6.67 
(m, 8H, Ar–H), 5.67–5.62 (d, 1H, J = 4.8 Hz, enaminic CH), 
3.82–3.72 (t, 4H, J = 12 Hz, 2COCH2CH2CH3 ), 3.02-2.94 (d, 
1H, J = 4.8, Ar-CH), 2.79–2.63 (m, 4H, 2CH2CH2CH3), 0.93 (t, 
6H, J = 7.5 Hz, 2CH3); MS m / z: 415 (M+ + 2), 413 (M+), 370 
(100); Anal. Calcd mass fractions of elements, w / %, for 
C23H25ClN2O3 (Mr = 412.90) are: C, 66.90; H, 6.10; N, 6.78. 
Found: C, 66.65; H, 5.75; N, 6.45. 
α-Glucosidase Inhibitory Assay  
The α-glucosidase (Sigma-Aldrich) inhibitory activity was 
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with slight modifications. 1 mg of each sample or acarbose 
at different concentrations (500 µL) of 1.0 U mL–1 α-
glucosidase solution in 100 mM phosphate buffer (100 mM, 
pH 6.8) at 37 °C for 20 minutes. The absorbance of the 
released p-nitrophenol was measured at 405 nm. The 
inhibition percentage was calculated using the given 
formula: Inhibition % = Abs control – Abs sample x 100. 
 
RESULTS AND DISCUSSION 
The heterocyclization of 2,3-dibromo-1,3-diarylpropan-1-
one 1a,b was investigated with the aim of obtaining some 
better antimicrobial heterocyclic derivatives in a facile 
route according to the process depicted in scheme 1. The 
synthetic strategy for the chemical transformation of 
dibromo ketone to heterocyclic systems depends upon the 
base induced dehydrobromination forming β-bromo 
unsaturated ketone conjugated addition of reagent 
nucleophilic center followed by heterocyclization through 
the loss of H2O. Thus, Treatment of methanolic solution of 
2,3-dibromo-1,3-diphenylpropan-1-one (1a) with 2-
aminobenzenethiol at room temperature, then heating 
under reflux afforded the cyclic product 2. The base 
mediated nucleophilic attack of thiolate anion to the more 
electrophilic carbon of dibromo ketone 1 followed by 
thiazine cyclization afforded benzothiazine derivative 2. The 
IR spectrum of compound 2 revealed the appearance of 
absorption bands at 3347 (NH) and 1677 (C=O) cm–1. It’s 1H 
NMR spectrum also showed a singlet at δ 3.61 ppm assigned 
to NH and two deshielded doublet of doublet at δ 6.69, 5.78 
ppm attributed for (SCHCO) and (Ar-CH) protons as well as 
mass spectrum showed ion peaks at m / z = 333 (M+ + 2), 332 
(M+ + 1), 331 (M+) which confirmed their chemical structure. 
 The [3+3] cyclocondensation of compound 1b with urea 
in presence of AcONa via one-pot procedure afforded 5-bromo 
pyrimidin-2(1H)-one derivative 3 through the intermediate A 
that suffer air oxidation leading to the final product. IR 
spectrum of the pyrimidinone 3 showed absorption band at 
1653 cm–1 assigned to carbonyl group and its 1H NMR 
spectrum showed a singlet at δ 8.07 ppm indicated the 
formation of aminic (NH) and aromatic protons were observed 
at δ 8.06–7.06 ppm that confirmed the structure. Also, mass 
spectrum of 3 showed molecular ion peak at m / z 392 
corresponding to its molecular formula C17H12BrClN2O2. 
 Although the detailed mechanism of above reaction 
remains not to be fully clarified, the formation of 
compound 3 could be explained by a reaction sequence 
presented in scheme 2. We proposed that the reaction 
proceeded via a reaction sequence of dehydrobromination, 
Michael type addition, cyclization and dehydration. 
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 Furthermore, the kinetic controlled thiazine deriva-
tive 4 was readily obtained through smooth dehydrobro-
mination of the dibromide 1b followed by the S-alkylation 
of thiourea and subsequent thiazine cyclization via losing 
H2O (Scheme 1). The postulated mechanism of formation 
of the thiazine 4 was outlined in details in scheme 3. 
 Appearance of absorption bands of NH groups in the 
IR spectrum of compound 4 at 3417 cm–1 and its 1H NMR 
spectrum revealed a singlet at δ 3.78 (Ar–CH), a multiplet δ 
8.21–7.04 (Ar–H + D2O exchangeable NH) as well as the 
mass spectrum showed ion peaks at m / z 411 (M+ + 2) and 
410 (M+ + 1) confirmed its molecular formula. 
 Refluxing of ethanolic solution of compound 1b and 
semicarbazide in presence of AcONa afforded dihydro-
pyrimidin-2(1H)-one derivative 5 (Scheme 1). This was 
potentiated from spectral analysis which revealed a peaks at 
3450 (NH), 3287, 3221 (NH2) 1677, (C=O) cm–1 and the 1H NMR 
spectrum showed a singlet at δ 6.60 ppm (D2O exchangeable 
NH + NH2). 13C NMR spectrum exhibited two signals at δ 55.94, 
54.90 corresponding to methylenic CH and methoxy groups. 
MS showed a peaks at m / z 329, 328 (M+ – Br) that confirmed 
its molecular formula. It seemed that semicarbazide undergo 
[3 + 3] cycloaddition with the conjugated intermediate formed 
upon basic dehydrobromination of compound 1b followed by 
dehydration and isomerization resulting in the formation of 
dihydropyrimidine derivative 5 and none of pyrazole derivative 
F was obtained (Scheme 4). 
 Also, one-pot reaction of compounds 1a,b with 
hydrazine hydrate (99 %) / AcONa in ethanol under reflux 
afforded 4-bromopyrazole derivatives 6a and 6b. Absence 
of absorption bands in the latter series for carbonyl group 
in the IR spectra as well as in the 1H NMR spectra was 
characteristic for the 4-bromo-1H-pyrazoles. Thus, 
Compound 6a were characterized with absorption band at 
3445 cm–1 for (NH) group and absence of the carbonyl in 
the IR spectrum. Its 1H NMR spectrum showed signal at δ 
13.35 ppm attributed to NH (D2O exchangeable) and the 
mass spectrum showed ion peaks at m / z 301, 299 and 222 
corresponding to (M+ + 2), (M+) and (M+ – C6H5), respectively 
which confirmed its chemical structure. IR spectrum of 
compound 6b exhibited absorption band at 3280 cm–1 for 
(NH). A multiplet at δ 7.98–7.10 ppm assigned to (Ar-H + 
D2O exchangeable NH) in the 1H NMR spectrum and char-
acteristic signals for bromopyrazole showed in 13C NMR 
spectrum. Also the mass spectrum showed molecular ion 
peak at m / z 363 and (M+ + 2) at 365 that confirmed its 
molecular formula C16H12BrClN2O. The formation of com-
pounds 6a and 6b could be explained by a reaction 
sequence presented in scheme 5. 
 We proposed that the bromopyrazole derivatives 
6a/6b were obtained as the result of dehydrobromination, 
Michael type addition and subsequent intramolecular 
cyclodehydration. 
 Using the behavior of α,β-unsaturated carbonyl 
system 7 which seemed to be of suitable located 
functionality towards some nitrogen and/or active 
methylene nucleophilic reagents was investigated. The 
mechanistic pathway for these heterocyclization depends 
upon 1,4-addition followed by intramolecular 
cyclodehydration and air oxidation in some cases. Thus, 
when chalcone 7a was allowed to react with tert-Butyl 
carbazate, cyclization occurred smoothly by heating 
under reflux to afford pyrazole 8 as shown in scheme 6. It 
presumably that the pyrazole derivative 8 was obtained 
via [3 + 2] intermolecular cycloaddition through the α-
nitrogen of the nucleophilic reagent were added 
exclusively to α,β-unsaturated system with simultaneous 
ring closure. Hence, the structure of compound 8 was 
characterized with absorption bands at 3426 (NH), 1707 
(C=O) cm–1 in IR spectrum and the presence of 
characteristic singlet at δ 10.81, 2.18 and 1.46 ppm in 1H 
NMR spectrum for NH, methinyl CH and tert-butyl 
protons, respectively. 
 The keeping of α,β-unsaturated carbonyl derivative 
7a with ammonium acetate/AcOH under reflux resulted in 
pyridine cyclization via the nonisolable β-amino-ketone 
followed by [3 + 3] cyclodehydration to furnish the 
dihydropyridine derivative, which in turn underwent 
dehydrogenation giving the final product 9 (Scheme 6). 
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 The analytical and spectral data were consistent with 
the proposed structure. Thus, the IR spectrum of 9 revealed 
a peak at 1658 cm-1 of the carbonyl group and the 1H NMR 
spectrum showed a multiplet at δ 8.27-7.09 indicating the 
Ar-H and CH pyridine protons and a singlet at δ 3.83 ppm 
according to 2OCH3 protons. 
 The high yield of α,β-unsaturated system of type 7 
encouraged us again to study their further reactivities to-
wards cyano methylene reagents. Pyridine of type 10 was 
formed upon the addition of malononitrile to ketonic deriv-
ative 7 in the presence of ammonia source. Thus, malono-
nitrile added its nucleophilic carbon to electrophilic carbon 
of 7a producing acyclic Michael type adduct that cyclizes 
intramolecularly in presence of AcONH4/AcOH producing 
pyridin-3-carbonitrile 10. While, α,β-unsaturated system 
7a,b when allowed to react with 5-methyl-2-phenyl-2,4-di-
hydro-3H-pyrazol-3-one afforded pyrazolo[3,4-b]pyridine 
of type 11 (Scheme 6). The analytical and spectral data of 
the obtained products were in agreement with the as-
signed structures. Thus, the 1H NMR spectrum of 10 
showed beside the expected signals of the pyridine moiety, 
a singlet at δ 3.36 ppm corresponding to D2O exchangable, 
NH2 group, a multiplet at  δ 8.12–6.93 ppm including the 
aromatic protons with CH pyridine and the IR spectrum ex-
hibited peak at 2217 cm-1 of the cyano group. 
 Also, the 1H NMR spectrum of product 11a (as an 
example) showed beside the expected signals of the pyra-
zolopyridine moiety, a multiplet at  δ 8.27–7.09 ppm 
including the aromatic protons with CH pyridine and the IR 
spectrum exhibited peak at 1600 (C=N) cm–1 and absence 
of carbonyl groups. The mass spectrum of product 11a 
revealed molecular ion peak at m / z = 426 that confirmed 
the postulated structure. 
 The reaction of α,β-ketonic derivative 7b with malo-
nonitrile in DMF/TEA afforded 2-imino-3,4-dihydro-2H-py-
ran-3-carbonitrile derivative 12 (Scheme 7). This reaction 
presumably proceeded via Michael addition followed by in-
tramolecular cyclization producing pyran derivative 12. The 
IR spectrum of compound 12 revealed the absence of car-
bonyl group and showed absorption bands at 3429, 3235, 
2202 and 1601 cm–1 for phenolic OH, iminic NH, CN groups 
as well as in the MS showed ion peaks at m / z 324 (M+) and 
323 (M+ – 1) confirmed its molecular formula. 
 Cycloaddition of cyanoacetamide with the chalcone 
7b in ethanolic EtONa solution afforded an Michael type ad-
ducts intermediate which in turn underwent basic cycliza-
tion followed by dehydrogenation producing pyran-3-
carbonitrile derivative 13 (Scheme 7). The analytical and 
spectral data was consistent with the proposed structure. 
Thus, the IR spectrum of compound 13 showed absorption 
bands at 3409, 2226, 1771, 1614 cm–1 for OH, CN, C=O and 
C=C groups, respectively. Its 1H NMR spectrum showed sig-
nal at 10.10 ppm assigned for OH group as well as in the MS 
showed ion peak at m / z 324 (M+ + 1), and 323 (M+) con-
firmed its molecular formula. 
 Also, chromenopyridine 14 was prepared by 
nucleophilic reaction of malonamide with 7b forming the 
nonisolable phenol A that undergo NH3 losing by 
intramolecular cyclization to give pyran ring (Scheme 8). 
Structure of 14 assigned by IR, 1H NMR and mass spectral 
data. In its IR spectrum, there are four bands assignable to 
NH, 2CO, C=C groups at 3433, 1777, 1638 and 1616 cm–1, 
respectively. 1H NMR spectrum showed deshielded singlet 
at 12.42 ppm attributed for NH (D2O exchangable) and 
aromatic protons were observed at δ 8.50–7.36 ppm. 
 The synthesis of 1-[2-butyryl-5-(4-chlorophenyl)-3-
(2-hydroxyphenyl)-2,3-dihydro-1H-pyrazol-1-yl]-1-butanone 
derivative 15 was achieved by intermolecular cycloaddition 
of hydrazine hydrate in the presence of butyric acid that 
form acylated pyrazole. Hence, refluxing of α,β–unsatu-
rated derivative 7b in presence of hydrazine hydrate 99 % 
in butyric acid yield the N–butanoyl product 15 (Scheme 8). 
 
Scheme 6. Synthesis of some pyrazole, pryridine and 
pyrazolo[3,4-b]pyridine derivatives. 
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The analytical and spectral data were consistent with the 
proposed structure. Thus, the IR spectrum of 15 revealed a 
peak at 3226 (OH) and 1638 cm–1 of the carbonyl groups and 
the 1H NMR spectrum showed a singlet at δ 9.62 ppm as-
signed for OH group, double doublet at δ 5.67 according to 
enaminic CH group of pyrazole, double doublet at δ 3.02 
indicating CH methylenic and a characteristic signals for the 
propyl groups. MS spectrum of 15 showed molecular ion 
peak at m / z = 413. 
Biological Activity  
The compounds bearing Pyrimidine, pyridine and/or 
pyrazole nucleus are well known to exhibit versatile range 
of biological activities such as anti-diabetic activities.[12–16] 
From the structure–activity relationships, it is revealed that 
the selected group of heterocyclic skeletons is important 
for anti-diabetic studies, which supports the previous 
results. For instance, the novel compounds 5, 8, 10, 11a and 
11b shared similar chemical features and functional groups, 
such as the presence of hydroxyl and methoxy groups were 
evaluated for their potential α-glucosidase inhibitory 
activity. The results are presented in Table 1. The activity 
comparison and the structure correlation of the tested 
group of the novel compounds had shown that these 
potencies paralleled the pyrazole moiety. 
 The pyrazole derivative 8 of the tested compounds 
were found to have less inhibitory (α-glucosidase 
inhibitory) activity than a commercial anti-hyperglycemic 
drug, acarbose (IC50 = 12.87 µM). The pyrazolo[3,4-
b]pyridin-4-yl]phenol derivative 11b was the most potent 
inhibitor (IC50 = 13.80 µM). Also, It was noted that the 
introduction of a 2-hydroxyphenyl group at position 4 on 
the condensed pyrazolopyridine moiety increased the 
activity (compound 11b), while the introduction of a 2-
methoxyphenyl group at position 4 on the condensed 
pyrazolopyridine moiety decreased the activity (compound 
11a), except for isolated pyrazole (Compound 8). These 
results indicate that hydroxylation of the condensed 
pyrazolopyridine rings is important for α-glucosidase 
inhibitory activity. 
 The IC50 value was defined as the concentration of 
alpha-glucosidase inhibitor to inhibit 50 % of its activity 
under the assayed conditions. All determinations were 
carried out in triplicate manner and values are expressed as 
the mean ± CD. Anti-diabetic activity of the tested 
compounds was depicted with IC50 value in Table 1. 
 
CONCLUSIONS 
In this work some novel condensed pyrimidine, pyrazole 
and pyridine derivatives were synthesized and assayed for 
their anti-diabetic inhibitory. The experimental work 
involves the synthesis of α,β-unsaturated carbonyls and 
α,β-dibromocarbonyls which was then heteroannelated 
with various 1,2; 1,3-bidentate nitrogen and carbon 
nucleophiles. Correlations are useful because they can 
indicate a predictive relationship that can be exploited in 
practice. Comparing of the anti-diabetic activity of the 
tested group of new compounds and its analogous 
described in the literature,[39–41] it is obvious that the 
highest activity might be attributed to the presence of 
pyrazolo[3,4-b]pyridine moiety bearing 2-HOC6H4 group. 
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